Firebrick Pharma Limited (AU:FRE) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Firebrick Pharma Ltd has extended its consulting agreement with Keith Shortall to boost sales of Nasodine in Singapore and explore partnerships across Asia. The six-month extension, starting in January 2025, includes a grant of 1.5 million share options to Shortall, contingent on meeting specific sales and partnership targets. This move signals Firebrick’s strategic push to strengthen its presence in the Asian pharmaceutical market.
For further insights into AU:FRE stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Apple’s (NASDAQ:AAPL) AI Connections Proving Troublesome
- Ford (NYSE:F) Sets Up New “Chief of Quality”
- Intel (NASDAQ:INTC) Slips as Shareholders Sue Over Foundry
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
